Janssen to Acquire Investigational Bermekimab from XBiotech
- Saturday, December 7, 2019, 7:07
- Finance
- Add a comment
HORSHAM, Pa., Dec. 7, 2019 /PRNewswire/ — Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today that it has entered a definitive agreement to acquire all rights to the investigational compound bermekimab from XBiotech Inc. Bermekimab is an…
About the Author
adminasapcorp has written 39510 stories on this site.